Absorbed dose (Gy/GBq) | ||||||||
Organ or lesion | No. of patients | Renal protection | Median | Range | Mean ± SD | Radionuclide for theranostics | Method | Reference |
Red marrow | 18 | No | 0.03 ± 0.01 | 111In | Blood | 20 | ||
5 | No | 0.17 | 0.15–0.19 | 0.17 ± 0.02 | 111In | Blood | 43 | |
8 | Yes | 0.06 ± 0.02 | 86Y | Blood | 47 | |||
Kidney | 18 | No | 3.3 ± 2.2 | 111In | Planar | 20 | ||
5 | No | 3.0 | 1.9–3.6 | 2.8 ± 0.6 | 111In | Planar | 43 | |
4 | No | 4.8 | 3.1–5.2 | 4.4 ± 1.0 | 86Y | PET | 44 | |
6 | Yes | 1.8 | 1.4–2.0 | 1.7 ± 0.3 | ||||
17 | Yes | 3.8 | 1.9–7.6 | 111In | SPECT | 45 | ||
8 | Yes | 0.6–2.8 | 1.7 ± 0.9 | 86Y | PET | 47 | ||
8 | No | 6.1 | 111In | Planar | 56 | |||
Tumor | 18 | No | 9.6 | 1.4–31 | 10.1 ± 7.5 | 111In | Planar | 20 |
5 | No | 12.2 | 2.4–41.7 | 16.0 ± 14.6 | 111In | Planar | 43 | |
4 | No | 2.0 ± 0.7 | 86Y | PET | 44 | |||
6 | Yes | 2.1 ± 0.7 | ||||||
24† | 0.4–16.5 | |||||||
17 | Yes | 3.8 | 0.9–5.4 | 111In | SPECT | 45 | ||
8 | Yes | 2.1–29.5 | 9.0 ± 6.6 | 86Y | PET | 47 |